stoxline Quote Chart Rank Option Currency Glossary
  
uniQure N.V. (QURE)
13.25  -0.93 (-6.56%)    02-18 16:00
Open: 14.04
High: 14.42
Volume: 639,767
  
Pre. Close: 14.18
Low: 13.2104
Market Cap: 708(M)
Technical analysis
2025-02-18 4:46:31 PM
Short term     
Mid term     
Targets 6-month :  17.8 1-year :  19.62
Resists First :  15.24 Second :  16.79
Pivot price 14.72
Supports First :  12.72 Second :  10.58
MAs MA(5) :  13.42 MA(20) :  14.93
MA(100) :  10.56 MA(250) :  7.63
MACD MACD :  -0.4 Signal :  -0.1
%K %D K(14,3) :  20.5 D(3) :  17.5
RSI RSI(14): 40
52-week High :  19.18 Low :  3.73
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ QURE ] has closed above bottom band by 17.7%. Bollinger Bands are 3.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 14.45 - 14.52 14.52 - 14.58
Low: 13.03 - 13.12 13.12 - 13.19
Close: 13.12 - 13.26 13.26 - 13.37
Company Description

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Headline News

Wed, 19 Feb 2025
uniQure (NASDAQ:QURE) Stock Passes Above Two Hundred Day Moving Average - Should You Sell? - MarketBeat

Tue, 18 Feb 2025
Palumbo Wealth Management LLC Takes $437,000 Position in uniQure (NASDAQ:QURE) - MarketBeat

Sat, 08 Feb 2025
Swelling losses haven't held back gains for uniQure (NASDAQ:QURE) shareholders since they're up 147% over 1 year - Simply Wall St

Mon, 27 Jan 2025
Is uniQure N.V. (QURE) the Most Promising Growth Stock According to Wall Street Analysts? - Yahoo Finance

Mon, 13 Jan 2025
Here’s Why uniQure N.V. (QURE) Is Skyrocketing - Insider Monkey

Sat, 11 Jan 2025
Is uniQure N.V. (QURE) Among the Best Growth Stocks to Buy and Hold in 2025? - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 53 (M)
Held by Insiders 3.564e+007 (%)
Held by Institutions 8.6 (%)
Shares Short 3,390 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.8932e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 776.9 %
Return on Equity (ttm) -16.7 %
Qtrly Rev. Growth 2.859e+007 %
Gross Profit (p.s.) 164.47
Sales Per Share -388.35
EBITDA (p.s.) -4.05474e+008
Qtrly Earnings Growth -5 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -179 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.04
Price to Cash Flow 4.41
Stock Dividends
Dividend 0
Forward Dividend 3.2e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android